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Background. Experimental murine models and human challenge studies of Salmonella Typhi infection have suggested that the 
gut microbiome plays an important protective role against the development of typhoid fever. Anaerobic bacterial communities have 
been hypothesized to mediate colonization resistance against Salmonella species by producing short-chain fatty acids, yet the com-
position and function of the intestinal microbiota in human patients with typhoid fever remain ill defined.
Methods. We prospectively collected fecal samples from 60 febrile patients admitted to Chittagong Medical College Hospital, 
Bangladesh, with typhoid fever or nontyphoidal febrile illness and from 36 healthy age-matched controls. The collected fecal samples 
were subjected to 16s rRNA sequencing followed by targeted metabolomics analysis.
Results. Patients with typhoid fever displayed compositional and functional disruption of the gut microbiota compared with 
patients with nontyphoidal febrile illness and healthy controls. Specifically, typhoid fever patients had lower microbiota richness and 
alpha diversity and a higher prevalence of potentially pathogenic bacterial taxa. In addition, a lower abundance of short-chain fatty 
acid–producing taxa was seen in typhoid fever patients. The differences between typhoid fever and nontyphoidal febrile illness could 
not be explained by a loss of colonization resistance after antibiotic treatment, as antibiotic exposure in both groups was similar.
Conclusions.  his first report on the composition and function of the gut microbiota in patients with typhoid fever suggests that the 
restoration of these intestinal commensal microorganisms could be targeted using adjunctive, preventive, or therapeutic strategies.
Keywords.  colonization resistance; microbiota; short-chain fatty acids; typhoid fever.
Typhoid fever (TF) is a systemic infection caused by the 
gram-negative bacteria Salmonella enterica serovar Typhi (S. 
Typhi). This debilitating condition, characterized by prolonged 
fever and a wide range of other nonspecific clinical signs, is 
common in areas of Asia and Africa that lack clean water and 
sanitation [1, 2]. Recent increases in antimicrobial resistance 
among several S. Typhi haplotypes have complicated treatment 
options, and mortality rates are estimated to range between 128 
000 to 161 000 deaths per year [3, 4]. Causes for the wide va-
riety of clinical presentations as well as the severity of infection 
are not understood but are hypothesized to be driven by altered 
interactions between Salmonella serovars and the host response 
[5, 6].
Research interest into the microorganisms that reside in 
our gastrointestinal tract—the gut microbiome—has surged in 
the last 2 decades. With the advent and improvement of tech-
nical and computational modalities to chart the microbiome, 
researchers have uncovered that these communities have im-
portant functions in the protection against enteric and systemic 
infectious diseases [7–9]. In homeostasis, bacterial communi-
ties residing in the gut are able to impair the growth of oppor-
tunistic and enteric pathogens, a process termed colonization 
resistance [7]. As an example, bacterial species and their prod-
ucts can provide direct colonization resistance by nutrient 
depletion and antimicrobial peptide production within the in-
testine, as well as indirectly by enhancement of the intestinal 
epithelial barrier and the upregulation of mucosal T helper 17 
(Th17) cells, group 3 innate lymphoid cells, and regulatory T 
cells [10].
Murine typhoid models with S.  typhimurium underscore 
the protective role of gut commensals, as it has been shown 
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that the presence of anaerobic microbiota-derived short-
chain fatty acids, such as butyrate and propionate, reduces the 
growth of the pathogen by reducing both the oxygen availa-
bility and pH levels of the gut environment [11–13]. In addi-
tion, S. typhimurium has been shown to be capable of exploiting 
microbiome-derived nutrients and oligosaccharides, which al-
lows for a growth advantage in the intestine over other potential 
pathogens, underscoring how these microbes are involved in 
an ongoing competitive colonization of the intestinal tract [14, 
15]. The notion that the gut microbiota could be of importance 
in protection against typhoid fever has recently been observed 
in humans. A  typhoid vaccine trial by Zhang and colleagues 
showed that differences in the composition and function of the 
gut microbiota in healthy adult volunteers were associated with 
altered host susceptibility to typhoid after challenge with wild-
type S. Typhi [16].
Despite this evidence of a close relationship between S. Typhi 
and the microbiome, there remains a significant knowledge gap 
concerning the association between typhoid fever infection and 
human gut microbiome composition. This study aimed to in-
vestigate how the gut bacterial composition and function of pa-
tients with typhoid fever might differ from patients with other 
febrile illnesses or healthy controls and how these differences 
might be correlated with short-term outcome in a prospec-
tive cohort of patients admitted to Chittagong Medical College 
Hospital (CMCH), a 1000-bed teaching hospital in Chittagong 
Division of Bangladesh.
METHODS
Study Design and Participants
Patients admitted to CMCH between January 15, 2012, and July 
5, 2012, were considered for enrollment, as described in pre-
vious studies conducted in this cohort [17–19]. Consecutive 
patients (≥16  years of age) who were admitted with an acute 
febrile illness (documented fever ≥38°C axillary, up to 48 hours 
after admission, history of fever <2 weeks) were recruited after 
giving informed written consent. Each study day, all the patients 
admitted to the wards were reviewed, and those with a history 
of fever of the appropriate duration had their temperature meas-
ured on at least 1 occasion. Eligible patients were then asked if 
they consented to participate in the study. Demographic and 
clinical information was recorded on a case record form at the 
time of admission and during the course of hospitalization.
A final diagnosis was made by the study team based on clin-
ical presentation, basic laboratory results, and microbiology 
results, as described earlier [17–19]. Fecal samples were col-
lected in plastic containers and were stored at −80°C within 24 
hours [20, 21]. A group of local Bangladeshi healthy volunteers 
were recruited to donate stools, which were stored in a similar 
manner to the patient population. The study protocol was ap-
proved by the National Research Ethics Committee (NREC) of 
Bangladesh (BMRC/NREC/2010–2013/1543) and the Oxford 
Tropical Research Ethics Committee (OXTREC reference 
25-11).
Microbiota Analysis
Fecal DNA was extracted and purified using a combina-
tion of bead-beating and the Maxwell 16 Tissue LEV Total 
RNA Purification Kit (Promega, Maddison, WI, USA), with 
Stool Transport And Recovery (STAR) buffer (Roche, Basel 
Switzerland) [22]. Polymerase chain reaction (PCR) products 
were purified using Ampure XP beads, and purified products 
were equimolar-pooled. The libraries were sequenced using an 
Illumina MiSeq platform (GATCBiotech, Konstanz, Germany) 
using V3 chemistry with 2×251 cycles [23]. Forward and re-
verse reads were truncated to 240 and 210 bases, respectively, 
and merged using USEARCH [24]. Merged reads that did not 
pass the Illumina chastity filter, had an expected error rate 
>2, or had <380 bases were filtered. Amplified sequence vari-
ants (ASVs) were inferred for each sample individually with 
a minimum abundance of 4 reads. Unfiltered reads were than 
mapped against the collective ASV set to determine the abun-
dances. Taxonomy was assigned using the RDP classifier [25] 
and SILVA30 16S ribosomal database V132 [26]. Given prior 
observations demonstrating the potential benefits of butyrate 
as an immunomodulatory compound [11, 12], we assessed this 
feature in our cohort by measuring the abundance of bacterial 
taxa that are known to be drivers of butyrate production, in ac-
cordance with a study that analyzed butyrate-producing path-
ways from 15 publicly available data sets [27].
Targeted Measurement of Short-Chain Fatty Acids
Sample preparation of fecal extracts and nuclear magnetic res-
onance (NMR) spectroscopy for quantification of short-chain 
fatty acids (SCFAs) was performed as described in Kim et al., 
with some modifications [28]. Briefly, aqueous extracts of feces 
were prepared by mixing 50–100  mg of feces and 0.3  mL of 
deionized water, followed by mechanical homogenization in a 
Bullet Blender 24 (Next Avance Inc, Troy, NY, USA). The fecal 
slurry was centrifuged twice at 18 213×g for 10 minutes at 4°C, 
and 0.225 mL of the supernatant was mixed with 0.025 mL of 
1.5-M potassium phosphate buffer (pH 7.4) containing 2 mM of 
sodium azide and 4 mM of sodium trimethylsilyl-propionate-d4 
(TSP-d4) in D2O. One proton NMR spectrum was acquired for 
each sample in a 14.1 T Avance II NMR (Bruker Biospin Ltd, 
Billerica, MA, USA). Quantification of SCFAs from the NMR 
data was performed in ChenomX (Chenomx NMR suite 8.4) 
using the known concentration of TSP-d4.
Statistics
Statistical analysis was performed in the R statistical frame-
work (version 3.5.1; R Foundation for Statistical Computing, 
Vienna, Austria). To assess alpha diversity, we calculated 
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the Shannon Diversity Index and Observed Taxa Richness 
index with the R phyloseq package [29]. Data were not nor-
mally distributed and are therefore presented as median (in-
terquartile range [IQR]), while data were analyzed using a 
Wilcoxon matched-pairs signed-rank test for paired data 
or a Mann-Whitney test for unpaired data. Beta diversity 
metrics were calculated using weighted and unweighted 
UniFrac on a rarefied data set, after which principal coor-
dinates analysis was performed to highlight the separation 
of microbiota composition based on antibiotic exposure and 
sampling time point. Differences in microbiota composition 
among groups and time points were tested for using permu-
tational multivariate analysis of variance (PERMANOVA) on 
beta diversity matrices using the vegan R package. False dis-
covery rate was adjusted for with Benjamini-Hochberg. To 
identify taxa that may be driving the significant differences 
detected between groups, differential abundance analysis 
was determined using DESeq2. Finally, potential predictors 
of outcome were assessed using linear regression models on 
log10-transformed relative abundances. Linear terms were 
confirmed by Wald tests in the rms R package (with P < .05 
indicating nonlinearity).
RESULTS
Demographic and Clinical Data
Fecal samples of a total of 60 patients with a febrile illness and 
36 healthy age-matched controls were collected. Fourteen of the 
60 patients were diagnosed with typhoid fever, either by positive 
blood cultures for S. Typhi (n = 8; 57.1%) or positive S. Typhi 
PCR in blood, urine, and/or feces (n = 6; 42.8%). A total of 46 
patients in the cohort were classified as having a nontyphoidal 
febrile illness (N-TF), of whom the majority were diagnosed 
with either a lower respiratory tract infection (36%) or urinary 
tract infection (27%). The baseline characteristics of all study 
participants are provided in Table 1. Patients with typhoid fever 
were slightly younger compared with nontyphoidal febrile ill-
ness patients and healthy controls (median age, 27 vs 35.5 vs 
35.0 years, respectively; P = .044), while no differences in med-
ical history were observed among the 3 groups. A comparison 
of clinical characteristics at admission showed that there were 
Table 1. Baseline Demographics and Disease Characteristics at Admission
Characteristic Healthy Controls (n = 36) Fever, No Typhoid (n = 46) Typhoid (n = 14) P Value
Age, median [IQR], y 35.50 [27.00–40.00] 35.00 [23.00–54.50] 27.00 [22.00–31.00] .044
Male sex, No. (%) 18 (50.0) 25 (54.3) 10 (71.4) .387
Past history of typhoid fever, No. (%) 3 (8.3) 8 (17.4) 2 (14.1) .513
Diabetes, No. (%) 2 (5.6) 6 (13.0) 0 (0.0) .189
Signs and symptoms     
 Headache, No. (%)  25 (54.3) 8 (57.1) 1.000
 Chest pain, No. (%)  10 (21.7) 0 (0.0) .088
 Cough, No. (%)  25 (54.3) 1 (7.1) .006
 Anorexia, No. (%)  21 (45.7) 8 (57.1) .818
 Abdominal pain, No. (%)  14 (30.4) 7 (50.0) .306
 Diarrhea, No. (%)  3 (6.5) 6 (42.9) .004
 Vomiting, No. (%)  17 (37.0) 8 (57.1) .302
 Constipation, No. (%)  6 (13.0) 2 (14.3) 1.000
 Dysuria, No. (%)  6 (13.0) 1 (7.1) .899
 Days of fever before admission, median [IQR]  4.00 [2.25–6.75] 6.00 [5.00–9.50] .048
Vital signs     
 Temperature, median [IQR]  38.90 [38.32–39.18] 38.55 [38.31–39.27] .888
 Pulse, median [IQR]  106 [92–116] 106 [96–110] .909
 Systolic blood pressure, median [IQR]  109 [100–120] 113 [101–120] .478
 Respiratory rate, median [IQR]  24 [20–36] 24 [21–32] .713
 Glasgow Coma Scale, median (IQR)  15 [15–15] 15 [15–15] .258
 White blood cell count, median [IQR]  12 800 [8200–16 000] 5850 [4300–9825] .002
 Hemoglobin, median [IQR]  11.60 [10.75–13.25] 12.60 [9.90–13.33] .431
 Platelets, median [IQR]  200 000 [170 000–250 000] 180 000 [162 500–230 000] .481
 Creatinine, median [IQR], mg/dL  1.00 [0.80–1.20] 0.90 [0.90–1.00] .263
 ALT, median [IQR]  27.50 [19.75–46.50] 57.5 [30.00–126.25] .003
 AST, median [IQR]  65.00 [48.25–84.75] 700.00 [245.25–2220.00] <.001
Outcome     
 Length of hospital stay, median [IQR], d  4.00 [3.00–5.00] 5.50 [4.00–8.50] .059
 Mortality, No. (%)  1 (2.2) 0 (0.0) 1.000
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; IQR, interquartile range.
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no apparent differences in clinical severity and subsequent 
length of hospital admission stay or mortality between TF and 
N-TF patients. TF patients had a longer duration of fever before 
admission, with more diarrhea, lower white blood cell counts, 
and higher aspartate transaminase (AST) and alanine transam-
inase (ALT) levels. There was more fluoroquinolone exposure 
in patients with TF before fecal sampling, but no differences in 
both exposure or duration of treatment with other antibiotic 
classes. An overview of infectious diagnoses, microbiological 
data, and antibiotic exposure before fecal sampling is depicted 
in Supplementary Table 1.
Typhoid Fever Is Characterized by Significantly Altered Patterns of 
Microbiota Disruption
Sequencing of fecal samples taken at the time of hospital ad-
mission yielded a total of 3 552 949 high-quality 16S rRNA gene 
sequences (average 37  010 per sample). We observed signifi-
cantly altered states of gut microbiota composition between 
TF- and N-TF patients compared with controls. On the micro-
biota phylum level, TF and N-TF patients showed a significant 
reduction in Actinobacteria (P  =  .04), while Proteobacteria 
were significantly enriched (P  =  .0001) (Figure  1A). In addi-
tion, major differences were observed between both patient 
groups and controls on a microbiota genus level. Importantly, 
potentially invasive bacterial genera were significantly more 
abundant in patients, including Enterococcus species (P < .0001) 
and Escherichia/Shigella species (P < .0001) (Figure 1).
Supplementary Figure 1 shows an overview of microbiota 
composition linked to a timeline of hospital stay and anti-
biotic exposure for each TF and N-TF patient. An unbiased 
comparison of microbial taxa in gut communities showed that 
typhoid fever is characterized by a distinct composition of the 
microbiome when compared with patients with a nontyphoidal 
febrile illness. On the genus level, TF subjects were shown to be 
significantly more colonized by Streptococcus, with a decrease in 
“beneficial” obligate anaerobic taxa, such as Ruminococcus spe-
cies, Faecalibacterium species, and other Lachnospiraceae when 
compared with N-TF patients (Supplementary Figure 2).
In tandem with the differences in community composi-
tion, strong alterations were observed in microbiota alpha di-
versity and richness between patients with typhoid fever and 
nontyphoidal febrile illness (N-TF vs control vs TF: median 
Shannon, 3.71 vs 3.96 vs 3.31; Wilcoxon, P = .048 and P = .004, 
respectively; median Observed Taxa, 390 vs 468 vs 308; 
Wilcoxon, P = .008 and P < .001, respectively) (Figure 2A and 
B). In addition, community richness was significantly lower in 
TF patients compared with N-TF patients (Wilcoxon, P = .040). 
Similar patterns were observed in beta diversity metrics of the 
microbiota (Figure 2C and D), as samples that were collected 
from TF and N-TF patients differed from controls in both 
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weighted and unweighted UniFrac analyses (PERMANOVA, 
P < .0001 and P < .0001) (Supplementary Table 2). Notably, beta 
diversity between TF and N-TF patients was comparable in 
the weighted UniFrac model, but was significantly altered with 
an unweighted UniFrac approach (PERMANOVA, P  =  .014) 
(Supplementary Table 2), which suggests that the taxa that drive 
the separation between TF and N-TF patients are of relatively 
low abundance.
Lower Abundance of Short-Chain Fatty Acids Producing Taxa in Typhoid 
Fever, With Diminished Fecal Butyrate, Acetate, and Propionate Levels
TF patients had a profoundly lowered abundance of butyrate-
producing genera, compared with both N-TF patients and 
healthy controls (N-TF vs TF vs control; median % of total 
sequences, 12.0 vs 6.9 vs 12.4; Wilcoxon, P = .020 and P = .009, 
respectively) (Figure 3A). We subsequently performed targeted 
NMR analysis to measure volatile short-chain fatty acids on a 
different aliquot of the same fecal samples and found that the 
measured fecal concentrations of butyrate, acetate, and propi-
onate were significantly diminished in TF patients compared 
with controls (Figure 3B–D). Of note, the fecal concentration 
of butyrate strongly correlated with the abundance of butyrate-
producing bacteria (R = .76; P < .0001) (Supplementary Figure 
3). Finally, linear regression analysis indicated that low diversity 
and low abundance of butyrate-producing bacteria were not as-
sociated with length of hospital stay in both TF and N-TF pa-
tients (Supplementary Figure 4A and B).
DISCUSSION
In this prospective observational study conducted at 
Chittagong Medical College Hospital, Bangladesh, we found 
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that patients with typhoid fever had significantly altered pat-
terns of compositional and functional disruption of the gut 
microbiota compared with patients with nontyphoidal febrile 
illness and healthy local controls. Specifically, TF patients had 
lower microbiota richness and alpha diversity, lower amounts 
of obligately anaerobic bacteria and fecal short-chain fatty 
acids, and a higher prevalence of potentially pathogenic bacte-
rial taxa in the gut when compared with nontyphoidal febrile 
patients. The marked differences we observed between TF and 
N-TF patients cannot be fully explained by an altered exposure 
to antibiotics. Typhoid fever patients were exposed to more 
fluoroquinolones, which are known to have little effect on the 
butyrate-producing compartment of the microbiota [30, 31], 
whereas exposure to beta-lactam antibiotics and metronidazole 
was comparable between groups. In addition, the total amount 
of antibiotic exposure between groups before hospital admis-
sion did not differ.
We identify 2 potential reasons that could explain the typical 
characteristics of the typhoid fever microbiome as observed in 
our cohort of patients. First, S. Typhi infection itself will most 
likely alter the intestinal environment, leading to an aerobic 
expansion and a loss of obligate anaerobic bacteria. This has 
been observed in preclinical models with S.  typhimurium by 
the Bäumler lab [11, 12]. Second, patients with TF could have 
a disrupted microbiome before the development of TF, poten-
tially increasing their risk of initial infection due to reduced 
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Figure 3. Lower amount of anaerobic bacteria with equally low abundance of fecal short-chain fatty acids in fecal samples of typhoid fever patients. Relative abundance of 
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colonization resistance. For example, the ultra-low amounts of 
short-chain fatty acids observed in this cohort with TF—and 
their potential relationship with acidification-mediated resist-
ance in the gut environment [13]—could benefit expansion of 
S. Typhi bacteria in the intestine and increase the a priori risk 
of developing TF.
An important limitation of this cohort study is the small 
sample size and limited follow-up. Given these limitations, 
no significant association was detected between either low di-
versity or low abundance of butyrate-producing bacteria and 
length of hospital admission. However, there is evidence that 
dysbiosis could have a negative impact on long-term outcomes, 
as it has been shown that some of the bacterial species consti-
tuting the intestinal microbiota contribute to protection against 
both enteric and systemic infections. For example, systemic ex-
posure of microbiota-derived ligands, such as flagellin and lip-
opolysaccharide, increases the activity of alveolar macrophages 
and bone marrow–derived neutrophils, which enhances the 
killing of gram-positive and gram-negative pathogens in the 
lung [32–36]. In addition, studies in mice have implicated that 
microbiota-derived butyrate restores IL-10 levels in the lung 
and the intestine by inhibiting histone deacetylase 3 (HDAC3), 
which contributes to microbiota-induced immunomodulation 
[37, 38]. We observed a similar importance of these microbial 
communities in a cohort study of patients receiving allogeneic 
hematopoietic stem cell transplant, as patients who harbored a 
high abundance of butyrate-producing bacteria were less likely 
to develop viral lower respiratory tract infections compared 
with patients who lost these bacterial species [30].
The consequences of typhoid fever infection on altered 
immunomodulation have also been described previously; 
transcriptional profiling of peripheral blood to investigate the 
host response of 29 individuals who contracted the disease in 
Vietnam showed that the infection induced a distinct immu-
nosuppressive signature in peripheral blood that persisted for 
1–9  months after acute infection [39]. Patients who retained 
this immunosuppressive signature were thought to be more 
susceptible to reinfection or relapse [40, 41], and one could hy-
pothesize that TF-induced dysbiosis could potentially play a 
role in this phenomenon.
Given the aforementioned evidence of the role of the micro-
biota in systemic priming of immune responses and the exten-
sive amount of disruption of the microbiota observed in our 
cohort, it is vital to investigate new treatment strategies that 
preserve these microorganisms during infection. For example, 
overuse of antibiotics and their associated transient alteration of 
the microbiota have implications for outcome, which was sup-
ported by a recent systematic review that found a statistically 
significant association between antibiotic exposure and subse-
quent risk of community-acquired infections [42]. In addition, 
our study highlights a new opportunity for the development of 
next-generation pre- or probiotics to enhance the abundance 
of obligate anaerobic bacteria as a potential adjuvant therapy 
during or following the treatment of TF and other infectious 
diseases.
Other limitations of this study include the cross-sectional 
setup, which limited our ability to provide clear insights on both 
the causes and long-term consequences of TF-related dysbiosis. 
In addition, the single-center setup of this cohort might not 
be fully comparable to other study settings, where exposure 
to microbial pathogens, antimicrobial treatment, and sanita-
tion measures differ. Therefore, both large longitudinal cohort 
studies and additional human-controlled S. Typhi challenge 
models are warranted to further uncover the intricate crosstalk 
between S. Typhi, the intestinal microbiota, and its host.
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